Telaprevir ILLUMINATE Study May Light The Way To Shortened Hep C Treatment Time
This article was originally published in The Pink Sheet Daily
Executive Summary
Vertex released solid top-line data from a second Phase III study supporting a response-guided regimen that could halve the current 48-week standard course for many patients.
You may also be interested in...
Vertex, Merck Face Education Challenge With Complex Hep C Regimens
With two direct acting antivirals now pending at FDA, the hepatitis C community is excited about adding efficacious new drugs to standard of care. But the regimens aren't as simple as that sounds; once the therapies are approved, the sponsors will have a considerable education effort on their hands, as physicians and patients work their way through the new HCV treatment calculus.
Vertex, Merck Face Education Challenge With Complex Hep C Regimens
With two direct acting antivirals now pending at FDA, the hepatitis C community is excited about adding efficacious new drugs to standard of care. But the regimens aren't as simple as that sounds; once the therapies are approved, the sponsors will have a considerable education effort on their hands, as physicians and patients work their way through the new HCV treatment calculus.
Telaprevir’s Hidden Talents: New Data Show Effectiveness In Difficult To Cure Populations
Groups with historically poor responses to standard hepatitis C therapy made good progress when the direct-acting antiviral telaprevir was added to their regimen, Vertex Pharmaceuticals Inc. reported at the American Association for the Study of Liver Diseases Meeting in Boston.